Hybrid Nanoparticles for Cancer Imaging and Therapy

Abstract

Hybrid nanoparticles, composed of both inorganic and organic components, have been exploited as promising platforms for cancer imaging and therapy. This class of nanoparticles can not only retain the beneficial features of both inorganic and organic materials, but also allow systematic fine-tuning of their properties through the judicious combination of functional components. This chapter summarizes recent advances in the design and synthesis of hybrid nanomaterials, with particular emphasis on two main categories of hybrid nanoparticles: Nanoscale metal-organic frameworks (also known as nanoscale coordination polymers) and polysilsesquioxane nanoparticles. Preliminary applications of these hybrid nanoparticles in cancer imaging and therapy are described.

MOF materials as therapeutic agents, drug carriers, imaging agents and biosensors in cancer biomedicine: Recent advances and perspectives

“…In the same study the drug c,c,t-[PtCl 2 (NH 3 ) 2 (Oet)O 2 CCH 2 CH 2 CO 2 H] (ethoxysuccinato-cisplatin), was attached to the amine group of the ligand of the nanoamino-MIL-101 with the loading equal to 12.8% (w/w) [9,80]. Comparing to noncovalent bonding approach, the covalent bonding prevents premature drug delivery because the drug is usually delivered after degradation of the whole structure [63].…”

Surface‐functionalised hybrid nanoparticles for targeted treatment of cancer

“…Hybrid NPs, consisting of both organic and inorganic components, have been used as promising tools for cancer therapy and imaging. This class of NPs not only preserves the beneficial characteristics of both organic and inorganic materials but also enables the systematic fine‐tuning of their properties through a sensible combination of functional components [29]. Hybrid NPs are engineered for the co‐delivery of combination treatments, which include chemotherapeutics and biologics, multiple chemotherapeutics, chemotherapeutics and radiotherapy, and chemotherapeutics and photodynamic therapy (PDT) [30].…”

Nanotherapeutics for multiple myeloma

“…Among the materials used to manufacture the NP are lipids (micelles, liposomes, stealth liposomes), polymers (polymeric micelles, dendrimers), inorganic materials (metal core, silica), drug conjugates (antibody-drug conjugates, polymer-drug conjugates, polymer-protein conjugates), and viral NP (Tran, DeGiovanni, Piel, & Rai, 2017). Additionally, development of hybrid nanoplatforms such as nanoscale metal-organic frameworks (NMOF), polysilsesquioxane (PSQ) nanoparticles (He & Lin, 2015), semiconducting polymer nanoparticles (J. Li, Rao, & Pu, 2018), and nanobody based platforms (Bannas, Hambach, & Koch-Nolte, 2017) is in progress.…”